Top videos | CashInVids – Watch Videos & Earn Money Online

Home
Articles

Top videos

All Time

Today

This week

This month

This year

Create Ai Influencer | Virtual Influencer | Ai Instagram Model 121gamers 107 Views • 2 years ago

Change your voice to virtual influencers for free → https://bit.ly/3NibLjU
Best free screen recorder and video editor you should try → https://bit.ly/3ttTCbR

In this video i will guide you through creating your AI influencer . Virtual influencers are taking the internet by storm.And some ai instagram models are making lot of money.You can also create Ai influencer in few easy steps.

First of all we will create ai models and will finalize one beautiful ai model girl. In second step we will change the environment of our virtual influencer images. In third step we will change the poses. In last step we will match the facial features of ai models.
In this way we can create hyper-realistic ai influencers.

Queries Solved :
ai influencer
create ai influencer
ai instagram model
ai influencers
ai model girl
ai model
ai influencer instagram
how to create ai influencer
virtual influencer
how to make ai influencer
how to create an ai influencer

▶Time Stamps:
00:00 Intro
00:31 Generating Ai Model face
01:47 Change Clothes of Ai Influencer
02:19 Change Environment
02:48 Change Pose
03:20 Matching Face of Ai Influencer
04:26 Support Me

▶Support Me: buymeacoffee.com/alihassanrG

▶Negative Prompt:

(worst quality, low quality, normal quality, lowres, low details, oversaturated, undersaturated, overexposed, underexposed, grayscale, bw, bad photo, bad photography, bad art:1.4), (watermark, signature, text font, username, error, logo, words, letters, digits, autograph, trademark, name:1.2), (blur, blurry, grainy), morbid, ugly, asymmetrical, mutated malformed, mutilated, poorly lit, bad shadow, draft, cropped, out of frame, cut off, censored, jpeg artifacts, out of focus, glitch, duplicate, (airbrushed, cartoon, anime, semi-realistic, cgi, render, blender, digital art, manga, amateur:1.3), (3D ,3D Game, 3D Game Scene, 3D Character:1.1), (bad hands, bad anatomy, bad body, bad face, bad teeth, bad arms, bad legs, deformities:1.3)

▶Links:
Tensor art :https://tensor.art/models/619331836222519234
Face swap : https://discord.com/oauth2/authorize?client_id=1090660574196674713&permissions=274877945856&scope=bot
Face Swap Images For Free : https://youtu.be/QlzV7c1_DfQ?si=ecVg67fsxrSBnlUj

▶Business Inquiry/ Sponsorship
alihassanredzone@gmail.com

#aiinfluencer #aimodels #virtualinfluencers #planetai

Ivermectin research 121gamers 58 Views • 6 months ago

With Professor Colleen Aldous
Critical appraisal of multidrug therapy in the ambulatory
management of patients with COVID-19 and hypoxemia
Part II: Causal inference using the Bradford Hill criteria

https://www.jstage.jst.go.jp/a....rticle/antibiotics/7

We continue the critical appraisal of three published case series of 119 COVID-19 patients with hypoxemia, treated in the United States, Zimbabwe, and Nigeria with similar ivermectin-based multidrug treatments, to assess the available evidence supporting a causal relationship between treatment and reduction in hospitalizations and mortality. A narrative review was conducted to assess the Bradford Hill criteria for a causal association. We used a previously proposed refinement of the Bradford Hill criteria that reorganized them into three categories of direct, mechanistic, and
parallel evidence. The efficacy of the two most aggressive ivermectin-based
multidrug protocols is supported by the Bradford Hill criteria for temporality,
strength of association, biological gradient, biological plausibility, coherence, consistency, and analogy. The causal relation between the treatment of hypoxemic COVID-19 patients using these protocols and the reduction in hospitalizations and mortality is supported as an inference to the best explanation.

Critical appraisal of multidrug therapy in the ambulatory
management of patients with COVID-19 and hypoxemia
Part I. Evidence supporting the strength of association

https://faculty.utrgv.edu/elef....therios.gkioulekas/p

On March 11, 2020, Coronavirus Disease 2019 (COVID-19), the disease caused by the Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2), was declared a pandemic by the World Health Organization (WHO) [1]. Worldwide, 768,187,096 confirmed cases of COVID-19 and 6,945,714 deaths have been reported to the WHO as of June 21 2023, amounting to an average Case Fatality Rate (CFR) of 0.9% [2]. During 2020, while several governments and public health agencies were focused on contagion control and in-hospital patient care, several medical doctors from all around the world innovated and discovered early outpatient multidrug treatments using several repurposed medications in combination [3–15]. In the United States, several independent efforts coalesced into the formulation of a sequenced multidrug protocol [10, Fig. 3] (hereafter, McCullough protocol), which is based on the pathophysiological understanding of COVID-19 as a triphasic illness with three overlapping phases: (1) viral proliferation; (2) hyperinflammatory cytokine storm (COVID-19 pneumonia); and (3) thrombosis. McCullough’s protocol proposed a combination antiviral therapy for treating the viral proliferation phase, immunomodulators for treating the cytokine storm, and antiplatelet agents and antithrombotics for handling the thrombotic stage, based on risk stratification and how the disease presents in each individual patient. Thus, the McCullough protocol is an algorithmic treatment using sequenced multiple drugs in combination and customized to the individual patient and their response to treatment; no single drug is necessary nor sufficient to achieve treatment efficacy towards reducing hospitalizations and deaths. A recently published update of the McCullough protocol [16, Fig. 3] introduced some adjustments including virucidal nasal washes and oral gargles [17–24]. A large case series of 869 high-risk patients [25, 26], who were treated using an early version of the McCullough protocol, has been compared against population-level and historical controls [27], showing the existence of efficacy with respect to the reduction of mortality and hospitalizations, which is also resilient with respect to random selection bias, provided that patients are treated early enough within the first 3 to 5 days from the onset of illness. Indeed, an earlier study by Fazio et al.[28] showed that the ideal window of opportunity for initiating an effective early outpatient treatment of COVID-19 to prevent hospitalization is approximately within the first 3 days.